About GBT
GBT is a company based in San Francisco (United States) founded in 2011 was acquired by Pfizer in August 2022. GBT has raised $177.4 million across 4 funding rounds from investors including Pfizer, RA Capital and Perceptive Advisors. The company has 457 employees as of December 31, 2021. GBT operates in a competitive market with competitors including Editas Medicine, LogicBio, Kedrion, Modus Therapeutics and Cyclerion, among others.
- Headquarter San Francisco, United States
- Employees 457 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Global Blood Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of GBT
Unlock access to complete
Funding Insights of GBT
GBT has successfully raised a total of $177.4M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $48 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GBT
GBT has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, RA Capital and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked |
Investor details for GBT
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GBT
Investment portfolio details for GBT
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GBT
Detailed financials for GBT
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gbt Comparisons
Peer comparison for GBT
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GBT
GBT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, LogicBio, Kedrion, Modus Therapeutics and Cyclerion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| Locked | Locked | Locked |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
|
| Locked | Locked | Locked |
Therapies for sickle cell disease and diabetic nephropathy are developed.
|
Detailed competitors of GBT
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gbt
Complete news archive for GBT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GBT
GBT was founded in 2011 and raised its 1st funding round 1 year after it was founded.
GBT is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
GBT is a funded company, having raised a total of $177.4M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at GBT is 457.
GBT was founded in 2011 and is based in San Francisco, United States. Operations are centered on biotechnology, with small molecules developed specifically for sickle cell disease. The lead candidate, voxelotor (GBT440), is under investigation in Phase 3 clinical trials for this condition. Hemoglobin S polymerization is inhibited by the candidate through modulation of hemoglobins oxygen affinity.
GBT's top competitors include Editas Medicine, Kedrion and Emmaus Medical.
GBT has 6 investors. Key investors include Pfizer, RA Capital, Perceptive Advisors, Wellington, and Deerfield.